Currently, drug resistance, especially against cephalosporins and carbapenems, among
gram-negative bacteria is an important challenge, which is further enhanced by the limited …

The proliferation of extensively drug-resistant Gram-negative pathogens has necessitated
the therapeutic use of colistin and polymyxin B. However, treatment failures with polymyxin …

Abstract Background. The US Food and Drug Administration (FDA) and European
Medicines Agency (EMA) have approved updated dose recommendations for intravenous …

Objectives The combination of aztreonam and avibactam has been proposed for the
treatment of infections caused by metallo-β-lactamase-producing Gram-negative organisms …

Objectives Polymyxin B is being increasingly utilized as a last resort against resistant Gram-
negative bacteria. We examined the pharmacodynamics of novel dosing strategies for …

Objectives Fosfomycin resistance occurs rapidly with monotherapy. This study systematically
investigated bacterial killing and emergence of fosfomycin resistance with fosfomycin …

Currently, in vitro synergy with colistin has not translated into improved clinical outcomes.
This study aimed to compare colistin combination therapy to colistin monotherapy in critically …

Development of spontaneous mutations in Pseudomonas aeruginosa has been associated
with antibiotic failure, leading to high rates of morbidity and mortality. Our objective was to …

Background: With increasing antibiotic resistance, the selection of effective treatment of A.
baumannii infections is particularly challenging. Methods: This study assessed the activities …

Polymyxins B and E (ie, colistin) are a family of naturally occurring lipopeptide antibiotics
that are our last line of defense against multidrug resistant (MDR) Gram-negative pathogens …